These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 21249319)

  • 21. Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma.
    Gadducci A; Viacava P; Cosio S; Cecchetti D; Fanelli G; Fanucchi A; Teti G; Genazzani AR
    Anticancer Res; 2003; 23(3C):3001-8. PubMed ID: 12926153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Feasibility study on biweekly paclitaxel treatment as maintenance chemotherapy in advanced müllerian carcinoma.
    Minagawa Y; Shimada M; Itamochi H; Sato S; Sato S; Okada M; Kitada F; Kigawa J
    Gynecol Obstet Invest; 2012; 73(4):272-6. PubMed ID: 22378216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
    Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.
    Umezu T; Shibata K; Kajiyama H; Terauchi M; Ino K; Nawa A; Kikkawa F
    Int J Gynecol Pathol; 2008 Apr; 27(2):207-12. PubMed ID: 18317222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
    Steffensen KD; Waldstrøm M; Jakobsen A
    Int J Gynecol Cancer; 2009 Jul; 19(5):820-5. PubMed ID: 19574766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).
    Emons G; Gorchev G; Sehouli J; Wimberger P; Stähle A; Hanker L; Hilpert F; Sindermann H; Gründker C; Harter P
    Gynecol Oncol; 2014 Jun; 133(3):427-32. PubMed ID: 24713545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome.
    Bagnoli M; Ambrogi F; Pilotti S; Alberti P; Ditto A; Barbareschi M; Galligioni E; Biganzoli E; Canevari S; Mezzanzanica D
    Endocr Relat Cancer; 2009 Jun; 16(2):443-53. PubMed ID: 19321593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
    Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
    Dizon DS; Restivo A; Lomme M; Charbonneau N; Brard L; Hughes T; Weitzen S; Legare R; Granai CO; Disilvestro P
    Am J Clin Oncol; 2008 Feb; 31(1):39-42. PubMed ID: 18376226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A retrospective study of advanced ovarian cancer in our ward].
    Baba T; Utsunomiya Y; Tamai A; Ueda M; Goto M; Nonogaki T
    Gan To Kagaku Ryoho; 2003 Dec; 30(13):2071-5. PubMed ID: 14712767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
    Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
    Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
    Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic results of cisplatin IP and carboplatin IV with G-CSF in patients with ovarian cancer.
    Adachi S; Itani Y; Ito K; Noda T; Shintani M; Saito K; Furukawa N; Tomii Y
    Oncol Rep; 2001; 8(1):27-31. PubMed ID: 11115564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma.
    Kowalski LD; Kanbour AI; Price FV; Finkelstein SD; Christopherson WA; Seski JC; Naus GJ; Burnham JA; Kanbour-Shakir A; Edwards RP
    Cancer; 1997 Apr; 79(8):1587-94. PubMed ID: 9118043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.
    Kusuda T; Shigemasa K; Arihiro K; Fujii T; Nagai N; Ohama K
    Oncol Rep; 2005 Jun; 13(6):1153-8. PubMed ID: 15870936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
    Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
    Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
    Elloul S; Elstrand MB; Nesland JM; Tropé CG; Kvalheim G; Goldberg I; Reich R; Davidson B
    Cancer; 2005 Apr; 103(8):1631-43. PubMed ID: 15742334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.
    Yoshida H; Sumi T; Zhi X; Yasui T; Honda K; Ishiko O
    Anticancer Res; 2011 Apr; 31(4):1271-7. PubMed ID: 21508375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.